NEW YORK (GenomeWeb) – Exact Sciences reported after the close of the market on Monday that its third quarter revenues rose 158 percent year over year, driven by a 136 percent increase in the number of completed Cologuard colon cancer tests.

For the three months ended Sept. 30, the molecular diagnostics company reported revenues of $72.6 million, up from $28.1 million a year earlier, and significantly beating analysts' consensus estimate of $65.0 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.